Download PDF

1. Company Snapshot

1.a. Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.


The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins.The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Show Full description

1.b. Last Insights on KPTI

Karyopharm Therapeutics' recent performance was positively driven by several factors. The company's Q2 2025 earnings call highlighted a 6% increase in U.S. XPOVIO net product revenue. Additionally, Karyopharm completed enrollment in the Phase 3 SENTRY trial in myelofibrosis, with top-line results anticipated in March 2026. The company also secured $100 million in financing, extending its cash runway into the second quarter of 2026. Furthermore, Karyopharm granted restricted stock units to newly-hired employees, indicating business growth and investment in talent.

1.c. Company Highlights

2. Karyopharm Therapeutics: Mixed Q3 Results, SENTRY Trial Progress

Karyopharm Therapeutics reported total revenue of $44 million in Q3 2025, a 13% increase year-over-year, with U.S. XPOVIO net product revenue growing 8.5% to $32 million. However, the company's GAAP net loss was $33.1 million, or $3.82 per share, missing analyst estimates of -$3.47 EPS. Gross-to-net provisions for XPOVIO remained consistent at 27%. License and other revenue was $12 million, up nearly 30% from the same period last year.

Publication Date: Nov -24

📋 Highlights
  • Phase III SENTRY Trial Enrollment Completed: - Myelofibrosis trial expected to report top-line data in March 2026, with 75% of physicians intending to adopt selinexor + ruxolitinib for frontline treatment.
  • Q3 Revenue Growth: - Total revenue reached $44M (13% YoY), U.S. XPOVIO net product revenue was $32M (8.5% YoY), with full-year guidance of $110–$120M for XPOVIO.
  • Combination Therapy Potential: - Selinexor + ruxolitinib has a $1B peak annual revenue opportunity in the U.S., supported by 75% physician intent for newly diagnosed high-risk patients.
  • Strong Liquidity Position: - Cash balance of $46.2M as of Q3 2025, sufficient to fund operations until Q2 2026, with adjusted full-year revenue guidance of $140–$155M.
  • Commercial Readiness: - 8.5% YoY XPOVIO revenue growth, favorable safety data in SENTRY, and a $32M net product revenue for Q3, backed by co-primary endpoints of SVR35 and TSS.

Commercial Performance and Guidance

The company is confident in its ability to deliver within its full-year guidance range of $110 million to $120 million for XPOVIO net product revenue. Sohanya Cheng highlighted the potential commercial opportunity in myelofibrosis, citing high unmet need and the potential for a transformative change in treatment. The company's existing commercial capabilities are well-positioned for a rapid and successful launch of selinexor plus ruxolitinib, if approved.

SENTRY Trial Progress and Potential

The SENTRY trial has completed enrollment, with top-line results expected in March 2026. Reshma Rangwala emphasized the need for new treatment options in myelofibrosis, and preliminary blinded aggregate safety data showed a favorable safety profile for the combination therapy. The trial's design and patient population were also discussed, with a focus on co-primary endpoints of SVR35 and absolute TSS. As Richard Paulson noted, the combination of selinexor and ruxolitinib may redefine the standard of care, offering a potentially foundational mechanism in myelofibrosis and other hematological malignancies.

Valuation and Outlook

With a P/S Ratio of 0.35 and an EV/EBITDA of -1.54, the stock appears to be undervalued relative to its revenue growth prospects. Analysts estimate next year's revenue growth at 3.2%. The company's cash balance was $46.2 million as of the end of Q3, and it expects to have sufficient liquidity to fund its planned operations into the second quarter of 2026. Delivering positive Phase III results could be a strong inflection point for the company, driving significant value for shareholders.

3. NewsRoom

Card image cap

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec -01

Source: prnewswire.com

Card image cap

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Dec -01

Source: prnewswire.com

Card image cap

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov -03

Source: prnewswire.com

Card image cap

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Nov -03

Source: seekingalpha.com

Card image cap

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Nov -03

Source: prnewswire.com

Card image cap

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct -27

Source: prnewswire.com

Card image cap

Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross

Oct -17

Source: zacks.com

Card image cap

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct -08

Source: benzinga.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Drugs

Expected Growth: 10.43%

Karyopharm Therapeutics Inc.'s 10.43% growth is driven by increasing adoption of its oral selective inhibitor of nuclear export (SINE) compounds, XPOVIO and SELINEXOR, in treating relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Strong clinical trial results, FDA approvals, and expanding commercial presence in the US and Europe also contribute to the growth.

7. Detailed Products

Xpovio

Xpovio is an oral, selective inhibitor of nuclear export compound for the treatment of relapsed or refractory multiple myeloma.

Nexodyn

Nexodyn is a topical gel formulation of Xpovio for the treatment of cutaneous T-cell lymphoma.

Verdinexor

Verdinexor is an oral, selective inhibitor of nuclear export compound for the treatment of various cancers, including multiple myeloma and lymphoma.

8. Karyopharm Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Karyopharm Therapeutics Inc. has a moderate threat of substitutes due to the presence of other pharmaceutical companies that offer similar products.

Bargaining Power Of Customers

Karyopharm Therapeutics Inc. has a low bargaining power of customers due to the specialized nature of its products, which limits customer switching.

Bargaining Power Of Suppliers

Karyopharm Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.

Threat Of New Entrants

Karyopharm Therapeutics Inc. has a high threat of new entrants due to the growing demand for pharmaceutical products and the relatively low barriers to entry.

Intensity Of Rivalry

Karyopharm Therapeutics Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 458.24%
Debt Cost 4.72%
Equity Weight -358.24%
Equity Cost 4.72%
WACC 4.72%
Leverage -127.91%

11. Quality Control: Karyopharm Therapeutics Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Mirum Pharmaceuticals

A-Score: 5.3/10

Value: 6.2

Growth: 7.6

Quality: 3.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Entrada Therapeutics

A-Score: 4.7/10

Value: 8.2

Growth: 8.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Karyopharm Therapeutics

A-Score: 3.8/10

Value: 9.8

Growth: 5.8

Quality: 6.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Spyre Therapeutics

A-Score: 3.6/10

Value: 6.8

Growth: 6.8

Quality: 5.6

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Vaxart

A-Score: 3.1/10

Value: 8.2

Growth: 4.3

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Palisade Bio

A-Score: 2.7/10

Value: 6.4

Growth: 5.7

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.75$

Current Price

5.75$

Potential

-0.00%

Expected Cash-Flows